Leukemia Clinical Trials

A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 611 clinical trials
  • 0 views
  • 16 Oct, 2022
  • 16 locations
Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML) (ENHANCE-3)

acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

carbon monoxide
hydroxyurea
azacitidine
cytarabine
ejection fraction
  • 0 views
  • 07 Oct, 2022
  • 17 locations
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Patients With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2)

The primary objective of this study is to compare the efficacy of magrolimab + azacitidine versus venetoclax + azacitidine in adults with previously untreated TP53 mutant acute myeloid leukemia

hydroxyurea
daunorubicin
ejection fraction
venetoclax
TP53
  • 1 views
  • 28 Oct, 2022
  • 71 locations
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia (SCOPE-L)

outcomes in patients with acute myeloid leukemia (AML).

Accepts healthy volunteers
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Randomized, Multicenter, Open-Label, Phase 3 Study to Compare the Efficacy and Safety of Acalabrutinib (ACP-196) in Combination With Venetoclax With and Without Obinutuzumab Compared to Investigator's Choice of Chemoimmunotherapy in Subjects With Previously Untreated Chronic Lymphocytic Leukemia Without Del(17p) or TP53 Mutation

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination with venetoclax with and without obinutuzumab compared to chemoimmunotherapy in subjects with previously untreated CLL.

acp-196
bendamustine
chemoimmunotherapy
acalabrutinib
venetoclax
  • 389 views
  • 13 Oct, 2022
  • 20 locations
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation (CRISTALLO)

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of ≤6 and a normal creatinine clearance of ≥70 mL/min) …

lymphoid leukemia
bendamustine
venetoclax
platelet count
cytopenia
  • 0 views
  • 27 Oct, 2022
  • 32 locations
A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

CC-90009-AML-002 is an exploratory Phase 1b, open-label, multi-arm trial to evaluate the safety and efficacy of CC-90009 in combination with anti-leukemia agents in participants with acute

hydroxyurea
flt3 internal tandem duplication
azacitidine
venetoclax
refractory acute myeloid leukemia (aml)
  • 21 views
  • 07 Oct, 2022
  • 19 locations
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia

igiv
chronic lymphocytic leukemia
primary infection
  • 8 views
  • 04 Oct, 2022
  • 29 locations
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

with Acute Myeloid Leukemia (AML) and AML secondary to myeloproliferative neoplasms (MPN). Participants must be relapsed/refractory (having failed prior therapy) and will be assigned to receive

decitabine
cytarabine
refractory acute myeloid leukemia (aml)
cancer
  • 2 views
  • 04 Oct, 2022
  • 55 locations
A Phase Ib, Multi-arm, Open-label, Study of HDM201 in Combination With MBG453 or Venetoclax in Adult Subjects With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

This is a phase 1b, multi-arm, open-label study of HDM201 in combination with MBG453 or venetoclax in subjects with AML or high-risk MDS. For all subjects, TP53wt status must be characterized by, at a minimum, no mutations noted in exons 5, 6, 7 and 8. Two treatment arms will enroll …

cytarabine
TP53
cell transplantation
induction chemotherapy
venetoclax
  • 67 views
  • 20 Oct, 2022
  • 7 locations